Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The isolation of a marker antigen from rat liver and pancreas tissue, which reacts with antibodies in a subtype of autoimmune hepatitis by complement fixation test, enzyme-linked immunosorbent assay and Western blot, is described. The liver-pancreas antigen could be detected in tissue from different human or animal organs, but liver and pancreas yielded the highest activity. A highly specific antigen fraction was obtained by gel filtration and ion exchange chromatography with a 100,000 g supernatant from rat liver tissue, and this preparation was shown to be devoid of nuclear, mitochondrial and microsomal antigens and cytokeratin 8 and 18, as demonstrated by appropriate marker antibodies. These data and absorption studies with cell organelles indicate that liver-pancreas antigen is a cytosolic protein. By Western blotting, two major epitopes at molecular weights 52 kD and 48 kD could be visualized. Sera from 175 patients previously shown to have high complement-fixing activity to a nonpurified liver-pancreas antigen fraction were further analyzed. All were positive by enzyme-linked immunosorbent assay with the purified liver-pancreas antigen fractions, and 111 were also positive by Western blot. Eighty-six sera reacted with the 52-kD determinant, 33 with the 48-kD determinant and 2 with both determinants. In 117 of the 175 patients, antibody to liver-pancreas antigen was associated with other autoantibodies known to characterize subgroups of autoimmune hepatitis. Thus 19 patients had antibodies to nuclei and 96 to actin but none to liver-kidney microsomes, hereby suggesting that antibody to liverpancreas antigen may define another subgroup of autoimmune hepatitis. Only 38 (9%) of 425 patients with autoimmune hepatitis types 1 (lupoid hepatitis) and 2 (liver-kidney microsome 1 antibody-positive hepatitis) and 4 (3%) of 128 patients with chronic hepatitis B and C were positive for the antibody to liver-pancreas antigen as tested by enzyme-linked immunosorbent assay. None of the 196 patients with nonhepatic disorders had this antibody type. A classification of three different subgroups of autoimmune hepatitis is proposed: type 1a, lupoid hepatitis (antinuclear antibody positive with or without actin antibody); type 1b, only actin antibody positive; type 2, liver-kidney microsome 1 antibody positive; and type 3, liver-pancreas antigen antibody positive (with or without other autoantibodies). With this classification, group 3 comprises around 30%. (Hepatology 1993;18:1-9.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement fixation with cell nuclei and DNA in lupus erythematosus
Robbins, W. C., Holman, H. R., Deicher, H., & Kunkel, H. G. (1957) · Experimental Biology and Medicine · doi:10.3181/00379727-96-23545 · Cited by 302
MITOCHONDRIAL ANTIBODIES IN PRIMARY BILIARY CIRRHOSIS
Berg, P. A., Doniach, D., & Roitt, I. M. (1967) · The Journal of Experimental Medicine · doi:10.1084/jem.126.2.277 · Cited by 201
Self-citation
Cited by
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Self-citationDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis
Wies, I., Brunner, S., Henninger, J., Herkel, J., Kanzler, S., zum Büschenfelde, K.-H. M., & Lohse, A. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02166-8 · Cited by 636
Diagnosis and treatment of autoimmune hepatitis
Czaja, A. J., & Freese, D. K. (2002) · Hepatology · doi:10.1053/jhep.2002.34944 · Cited by 563
Vergani, D., Alvarez, F., Bianchi, F. B., Cançado, E. L. R., Mackay, I. R., Manns, M. P., Nishioka, M., & Penner, E. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.002 · Cited by 446
“Anti-soluble liver antigen/liver–pancreas antigen (anti-SLA/LP) Two earlier described autoantibodies in AIH, anti-SLA [43] and anti-liver–pancreas [44], target the same antigen [45].”
BackgroundMieli-Vergani, G., Vergani, D., Czaja, A. J., Manns, M. P., Krawitt, E. L., Vierling, J. M., Lohse, A. W., & Montano-Loza, A. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.17 · Cited by 425
Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis
Czaja, A. J., & Manns, M. P. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.053 · Cited by 280
Ma, Y., Okamoto, M., Thomas, M. G., Bogdanos, D. P., Lopes, A. R., Portmann, B., Underhill, J., Dürr, R., Mieli-Vergani, G., & Vergani, D. (2002) · Hepatology · doi:10.1053/jhep.2002.32092 · Cited by 271
Prediction of short- and long-term outcome in patients with autoimmune hepatitis
Kirstein, M. M., Metzler, F., Geiger, E., Heinrich, E., Hallensleben, M., Manns, M. P., & Vogel, A. (2015) · Hepatology · doi:10.1002/hep.27983 · Cited by 136
Autoimmune hepatitis and its variant syndromes
BEN-ARI, Z., & CZAJA, A. J. (2001) · Gut · doi:10.1136/gut.49.4.589 · Cited by 102
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., & Vergani, D. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.004 · Cited by 61
“Autoimmune(-Like)” drug and herb induced liver injury: new insights into molecular pathogenesis
Sebode, M., Schulz, L., & Lohse, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091954 · Cited by 47
Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited
Berg, P. A., & Klein, R. (1995) · Liver · doi:10.1111/j.1600-0676.1995.tb00687.x · Cited by 43
Self-citation
Metadata
- Authors
- Stechemesser, E., Klein, R., & Berg, P. A.
- Venue
- Hepatology
- Published
- 1993-07
- Volume
- 18
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2011276676
- Cited by
- 144
- References
- 2
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.